Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers

Journal of Pharmaceutical Sciences

Volumn 99, Issue 7, 2010, Pages 3150-3165

  Tam, Jasmine M ^a   Engstrom, Josh D ^b   Ferrer, Domingo ^a   Williams III, Robert O ^c   Johnston, Keith P ^a  

^a The University of Texas at Austin   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Protein delivery; Pulmonary delivery absorption; Pulmonary drug delivery; Stabilization; Suspensions

Indexed keywords

FLUORINATED HYDROCARBON; ITRACONAZOLE; NANOPARTICLE; PROPELLANT;

ARTICLE; CONTROLLED STUDY; DENSITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; EVAPORATION; FLOCCULATION; FRACTIONAL ANISOTROPY; LUNG; METERED DOSE INHALER; PARTICLE SIZE; POROSITY; SUSPENSION;

EID: 77953299397     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22091     Document Type: Article

References (62)

1. Courrier HM, Butz N, Vandamme TF. 2002. Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19:425-498. (Pubitemid 36314479)
2. Bernstein JA, Amin H, Smith S. 2007. Therapeutic uses of lung aerosol. In: Hickey AJ, editor. Inhalation aerosols: Physical and biological basis for therapy, Second edition. New York, NY: Informa healthcare USA, Inc. pp. 219-252.
3. Benfait C. 2004. Kos reports achievements of new research and development milestones. Kos Press Release press release online at: http://www.kospharma. com/files/8262004.pdf
4. Edwards D, Hanes J, Caponetti G, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary delivery. Science 276:1868-1871. (Pubitemid 27443665)
5. Patton JS. 2005. Unlocking the opportunity of tight glycaemic control: Innovative delivery of insulin via the lung. Diabetes Obes Metab 7:S5-S8.
6. Patton JS, Bukar JG, Eldon MA. 2004. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781-801. (Pubitemid 39382220)
7. White S, Bennett DB, Cheu S, Conley PW, Guzek DB, Gray S, Howard J, Malcolmson R, Parker JM, Roberts P, Sadrzadeh N, Schumacher JD, Seshadri S, Sluggett GW, Stevenson CL, Harper NJ. 2005. EXUBERA: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 7:896-906. (Pubitemid 43133996)
8. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. 1986. Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu]m. J Aerosol Sci 17:811-825. (Pubitemid 17492310)
9. Heyder J, Rudolf G. 1984. Mathematical models of particle deposition in the human respiratory tract. J Aerosol Sci 15:697-707. (Pubitemid 15437588)
10. Smyth HDC. 2003. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 55:807-828.
11. Terzano C. 2001. Pressurized metered dose inhalers and add-on devices. Pulm Pharmacol Ther 14:351-366. (Pubitemid 32977018)
12. Rogueda P. 2005. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv 2:625-638. (Pubitemid 41038676)
13. Steckel H, Markefka P, te Wierik H, Kammelar R. 2006. Effect of milling and sieving on functionality of dry powder inhalation products. Int J Pharm 309:51-59.
14. Williams RO III, Brown J, Liu J. 1999. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Technol 4:167-179. (Pubitemid 29211018)
15. Williams RO III, Repka MA, Barron MK. 1999. Application of co-grinding to formulate a model pMDI suspension. Eur J Pharm Biopharm 48:131-140.
16. Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. 1999. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 16:555-561.
17. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, Weers JG. 2000. Hollow porous particles in metered dose inhalers. Pharm Res 17:168-174.
18. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. 1999. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735-1742.
19. Michael Y, Snowden MJ, Chowdhry BZ, Ashurst IC, Davies-Cutting CJ, Riley T. 2001. Characterisation of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system. Int J Pharm 221:165-174.
20. Williams RO III, Liu J. 1998. Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur J Pharm Sci 7:137-144.
21. Williams RO III, Liu J. 1998. Influence of formulation additives on the vapor pressure of hydrofluoroalkane propellants. Int J Pharm 166:99-103.
22. McDonald KJ, Martin GP. 2000. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm 201:89-107.
23. Johnson KA. 1996. Interfacial phenomena and phase behavior in metered-dose inhaler formulations. Lung Biol Health Dis 94: (Inhalation Aerosols) 385-415.
24. Selvam P, Peguin RPS, Chokshi U, da Rocha SRP. 2006. Surfactant design for the 1,1,1,2-tetrafluoroethane-water interface: Ab initio calculations and in situ high-pressure tensiometry. Langmuir 22:8675-8683.
25. Keller M. 1999. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int J Pharm 186:81-90.
26. Patton JS. 2005. Pulmonary drug delivery comes of age: The outlook for 2005 & beyond. Drug Deliv Technol 5:46-49.
27. Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr J, Newman SP. 2002. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res 19:258-264.
28. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. 2004. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res 21:1607-1614.
29. Weers JG, Tarara TE, Dellamary LA, Kabalnov A, Schutt EG. 1999. Stabilized preparations for use in metered dose inhalers. In: Nektar, editor. USA: Alliance Pharmaceutical Corporation. Inhale therapeutics systems Inc. San Carlos, CA p 58.
30. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. 2002. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 99:12001-12005.
31. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH. 2007. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: Effects of phospholipids. Int J Pharm 333:187-198.
32. Hadinoto K, Phanapavudhikul P, Zhu K, Tan RBH. 2006. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res 45:3697-3706.
33. Bailey MM, Gorman EM, Munson EJ, Berkland C. 2008. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 24:13614-13620.
34. Peek LJ, Roberts L, Berkland C. 2008. Poly(d,l-lactide-coglycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir 24:9775-9783.
35. Engstrom JD, Tam JM, Miller MA, Williams RO, Johnston KP. 2009. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm Res 26:101-117.
36. Patton JS. 1996. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 19:3-36.
37. Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, Kissel T. 2003. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 20:2011-2020.
38. Hiemenz PC, Rajagopalan R, editors. 1997. Principles of colloid and surface chemistry. 3rd edition, Marcel Dekker Inc. New York, New York Revised and Expanded. ed. p 688.
39. Philipse AP, Wierenga AM. 1998. On the density and structure formation in gels and clusters of colloidal rods and fibers. Langmuir 14:49-54.
40. Goodarz-Nia I, Sutherland DN. 1975. Floc simulation. Effects of particle size and shape. Chem Eng Sci 30:407-412.
41. Jiang Z, Guan Y. 2006. Flocculation morphology: Effect of particulate shape and coagulant species on flocculation. Water Sci Technol 53: (7, Particle Separation 2005: Waste Water Treatment): 9-16.
42. Philipse AP. 1996. The random contact equation and its implications for (colloidal) rods in packings, suspensions, and anisotropic powders. Langmuir 12:1127-1133.
43. Boal AK, Ilhan F, DeRouchey JE, Thurn-Albrecht T, Russell TP, Rotello VM. 2000. Self-assembly of nanoparticles into structured spherical and network aggregates. Nature 404:746-748.
44. Pison U, Welte T, Giersig M, Groneberg DA. 2006. Nanomedicine for respiratory diseases. Eur J Pharmacol 533:341-350.
45. Amidon GL, Lennernaes H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
46. Singhal D, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56:335-347.
47. Engstrom JD, Lai ES, Ludher B, Chen B, Milner TE, Kitto GB, Williams RO III, Johnston KP. 2008. Formation of stable submicron protein particles by thin film freezing. Pharm Res 25:1334-1336.
48. Rogers TL, Gillespie IB, Hitt JE, Fransen KL, Crowl CA, Tucker CJ, Kupperblatt GB, Becker JN, Wilson DL, Todd C, Broomall CF, Evans JC, Elder EJ. 2004. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res 21:2048-2057.
49. Matteucci ME, Hotze MA, Johnston KP, Williams RO III. 2006. Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir 22:8951-8959.
50. Wong J, Papadopoulos P, Werling J, Rebbeck C, Doty M, Kipp J, Neuberger D. 2004. American Association of Pharmaceutical Scientists Annual Meeting, Baltimore, MD, 2004.
51. Ryoo W, Webber SE, Johnston KP. 2003. Water-in-carbon dioxide microemulsions with methylated branched hydrocarbon surfactants. Ind Eng Chem Res 42:6348-6358.
52. Finlay WH. 2001. The mechanics of inhaled pharmaceutical aerosols, Edition Number 1. New York, NY. Academic Press.
53. Traini D, Young PM, Rogueda P, Price R. 2007. In vitro investigation of drug particulates interactions and aerosol performance of pressurized metered dose inhalers. Pharm Res 24:125-135.
54. Rogueda PGA. 2003. HPFP, a model propellant for pMDIs. Drug Dev Ind Pharm 29:39-49.
55. Traini D, Rogueda P, Young P, Price R. 2005. Surface energy and interparticle forces correlations in model pMDI formulations. Pharm Res 22:816-825. (Pubitemid 40768595)
56. Matteucci ME, Paguio JC, Miller MA, Williams RO III, Johnston KP. 2008. Flocculated amorphous nanoparticles for highly supersaturated solutions. Pharm Res 25:2477-2487.
57. Fargues C, Turchiuli C. 2004. Structural characterization of flocs in relation to their settling performances. Chem Eng Res Des 82:1517. (Pubitemid 38043199)
58. Tang P, Greenwood J, Raper JA. 2002. A model to describe the settling behavior of fractal aggregates. J Colloid Interface Sci 247:210-219. (Pubitemid 34953483)
59. Hough DB, White LR. 1980. The calculation of Hamaker constants from Lifshitz theory with applications to wetting phenomena. Adv Colloid Interface Sci 14:3-41.
60. Li H, Peng X, Wu L, Jia M, Zhu H. 2009. Surface potential dependence of the Hamaker constant. J Phys Chem C 113:4419-4425.
61. Tam JM, McConville JT, Williams RO III, Johnston KP. 2008. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 97:4915-4933.
62. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams RO. 2008. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 361:177-188.